Top

Current Osteoporosis Reports

Published in:

01-12-2019 | Cytokines | Osteoimmunology (M Nakamura and J Lorenzo, Section Editors)

Inflammation in Fibrodysplasia Ossificans Progressiva and Other Forms of Heterotopic Ossification

Authors: Koji Matsuo, Robert Dalton Chavez, Emilie Barruet, Edward C. Hsiao

Published in: Current Osteoporosis Reports | Issue 6/2019

Abstract

Purpose of review

Heterotopic ossification (HO) is associated with inflammation. The goal of this review is to examine recent findings on the roles of inflammation and the immune system in HO. We examine how inflammation changes in fibrodysplasia ossificans progressiva, in traumatic HO, and in other clinical conditions of HO. We also discuss how inflammation may be a target for treating HO.

Recent findings

Both genetic and acquired forms of HO show similarities in their inflammatory cell types and signaling pathways. These include macrophages, mast cells, and adaptive immune cells, along with hypoxia signaling pathways, mesenchymal stem cell differentiation signaling pathways, vascular signaling pathways, and inflammatory cytokines.

Summary

Because there are common inflammatory mediators across various types of HO, these mediators may serve as common targets for blocking HO. Future research may focus on identifying new inflammatory targets and testing combinatorial therapies based on these results.

Long F. Building strong bones: molecular regulation of the osteoblast lineage. Nat Rev Mol Cell Biol. 2011;13(1):27–38. https://doi.org/10.1038/nrm3254.CrossRefPubMed

Udagawa N. The mechanism of osteoclast differentiation from macrophages: possible roles of T lymphocytes in osteoclastogenesis. J Bone Miner Metab. 2003;21(6):337–43. https://doi.org/10.1007/s00774-003-0439-1.CrossRefPubMed

Nakagawa N, Kinosaki M, Yamaguchi K, Shima N, Yasuda H, Yano K, et al. RANK is the essential signaling receptor for osteoclast differentiation factor in osteoclastogenesis. Biochem Biophys Res Commun. 1998;253(2):395–400. https://doi.org/10.1006/bbrc.1998.9788.CrossRefPubMed

Yasuda H, Shima N, Nakagawa N, Yamaguchi K, Kinosaki M, Mochizuki S, et al. Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL. Proc Natl Acad Sci U S A. 1998;95(7):3597–602. https://doi.org/10.1073/pnas.95.7.3597.CrossRefPubMedPubMedCentral

Vi L, Baht GS, Whetstone H, Ng A, Wei Q, Poon R, et al. Macrophages promote osteoblastic differentiation in-vivo: implications in fracture repair and bone homeostasis. J Bone Miner Res. 2015;30(6):1090–102. https://doi.org/10.1002/jbmr.2422.CrossRefPubMed

Raggatt LJ, Wullschleger ME, Alexander KA, Wu AC, Millard SM, Kaur S, et al. Fracture healing via periosteal callus formation requires macrophages for both initiation and progression of early endochondral ossification. Am J Pathol. 2014;184(12):3192–204. https://doi.org/10.1016/j.ajpath.2014.08.017.CrossRefPubMed

Negishi-Koga T, Gober HJ, Sumiya E, Komatsu N, Okamoto K, Sawa S, et al. Immune complexes regulate bone metabolism through FcRgamma signalling. Nat Commun. 2015;6:6637. https://doi.org/10.1038/ncomms7637.CrossRefPubMed

Schett G. Effects of inflammatory and anti-inflammatory cytokines on the bone. Eur J Clin Investig. 2011;41(12):1361–6. https://doi.org/10.1111/j.1365-2362.2011.02545.x.CrossRef

Kaplan FS, Chakkalakal SA, Shore EM. Fibrodysplasia ossificans progressiva: mechanisms and models of skeletal metamorphosis. Dis Model Mech. 2012;5(6):756–62. https://doi.org/10.1242/dmm.010280.CrossRefPubMedPubMedCentral

10.

McCarthy EF, Sundaram M. Heterotopic ossification: a review. Skelet Radiol. 2005;34(10):609–19. https://doi.org/10.1007/s00256-005-0958-z.CrossRef

11.

Kocic M, Lazovic M, Mitkovic M, Djokic B. Clinical significance of the heterotopic ossification after total hip arthroplasty. Orthopedics. 2010;33(1):16. https://doi.org/10.3928/01477447-20091124-13.CrossRefPubMed

12.

Leung C, Casey AT, Goffin J, Kehr P, Liebig K, Lind B, et al. Clinical significance of heterotopic ossification in cervical disc replacement: a prospective multicenter clinical trial. Neurosurgery. 2005;57(4):759–63; discussion -63. https://doi.org/10.1093/neurosurgery/57.4.759.CrossRefPubMed

13.

Hurvitz EA, Mandac BR, Davidoff G, Johnson JH, Nelson VS. Risk factors for heterotopic ossification in children and adolescents with severe traumatic brain injury. Arch Phys Med Rehabil. 1992;73(5):459–62.PubMed

14.

Potter BK, Burns TC, Lacap AP, Granville RR, Gajewski DA. Heterotopic ossification following traumatic and combat-related amputations. Prevalence, risk factors, and preliminary results of excision. J Bone Joint Surg Am. 2007;89(3):476–86. https://doi.org/10.2106/JBJS.F.00412.CrossRefPubMed

15.

Beckmann JT, Wylie JD, Potter MQ, Maak TG, Greene TH, Aoki SK. Effect of naproxen prophylaxis on heterotopic ossification following hip arthroscopy: a double-blind randomized placebo-controlled trial. J Bone Joint Surg Am. 2015;97(24):2032–7. https://doi.org/10.2106/JBJS.N.01156.CrossRefPubMedPubMedCentral

16.

Evans KN, Forsberg JA, Potter BK, Hawksworth JS, Brown TS, Andersen R, et al. Inflammatory cytokine and chemokine expression is associated with heterotopic ossification in high-energy penetrating war injuries. J Orthop Trauma. 2012;26(11):e204–13. https://doi.org/10.1097/BOT.0b013e31825d60a5.CrossRefPubMed

17.

Forsberg JA, Potter BK, Polfer EM, Safford SD, Elster EA. Do inflammatory markers portend heterotopic ossification and wound failure in combat wounds? Clin Orthop Relat Res. 2014;472(9):2845–54. https://doi.org/10.1007/s11999-014-3694-7.CrossRefPubMedPubMedCentral

18.

Pakos EE, Ioannidis JP. Radiotherapy vs. nonsteroidal anti-inflammatory drugs for the prevention of heterotopic ossification after major hip procedures: a meta-analysis of randomized trials. Int J Radiat Oncol Biol Phys. 2004;60(3):888–95. https://doi.org/10.1016/j.ijrobp.2003.11.015.CrossRefPubMed

19.

• Barruet E, Morales BM, Cain CJ, Ton AN, Wentworth KL, Chan TV, et al. NF-kappaB/MAPK activation underlies ACVR1-mediated inflammation in human heterotopic ossification. JCI Insight. 2018;3(22). https://doi.org/10.1172/jci.insight.122958Analysis of FOP patient-derived sera and monocytes strongly indicates the contribution of myeloid cells in ACVR1-mediated inflammation.

20.

The International Clinical Consortium on FOP The medical management of fibrodysplasia ossificans progressiva: current treatment considerations. Clin Proc Intl Clin Consort FOP 2011:4:1-100.

21.

Baujat G, Choquet R, Bouee S, Jeanbat V, Courouve L, Ruel A, et al. Prevalence of fibrodysplasia ossificans progressiva (FOP) in France: an estimate based on a record linkage of two national databases. Orphanet J Rare Dis. 2017;12(1):123. https://doi.org/10.1186/s13023-017-0674-5.CrossRefPubMedPubMedCentral

22.

Shore EM, Xu M, Feldman GJ, Fenstermacher DA, Cho TJ, Choi IH, et al. A recurrent mutation in the BMP type I receptor ACVR1 causes inherited and sporadic fibrodysplasia ossificans progressiva. Nat Genet. 2006;38(5):525–7. https://doi.org/10.1038/ng1783.CrossRefPubMed

23.

• Hino K, Ikeya M, Horigome K, Matsumoto Y, Ebise H, Nishio M, et al. Neofunction of ACVR1 in fibrodysplasia ossificans progressiva. Proc Natl Acad Sci U S A. 2015;112(50):15438–43. https://doi.org/10.1073/pnas.1510540112This report reveals a novel mechaism of BMP signaling through mutated ACVR1 in FOP. CrossRefPubMedPubMedCentral

24.

• Hatsell SJ, Idone V, Wolken DM, Huang L, Kim HJ, Wang L, et al. ACVR1R206H receptor mutation causes fibrodysplasia ossificans progressiva by imparting responsiveness to activin A. Sci Transl Med. 2015;7(303):303ra137. https://doi.org/10.1126/scitranslmed.aac4358Activin A, a cytokine produced by many cell types including immune cells, appears to be a key driver of heterotopic ossification in FOP. CrossRefPubMedPubMedCentral

25.

Aykul S, Martinez-Hackert E. Transforming growth factor-beta family ligands can function as antagonists by competing for Type II receptor binding. J Biol Chem. 2016;291(20):10792–804. https://doi.org/10.1074/jbc.M115.713487.CrossRefPubMedPubMedCentral

26.

Olsen OE, Wader KF, Hella H, Mylin AK, Turesson I, Nesthus I, et al. Activin A inhibits BMP-signaling by binding ACVR2A and ACVR2B. Cell Commun Signal. 2015;13:27. https://doi.org/10.1186/s12964-015-0104-z.CrossRefPubMedPubMedCentral

27.

Shafritz AB, Shore EM, Gannon FH, Zasloff MA, Taub R, Muenke M, et al. Overexpression of an osteogenic morphogen in fibrodysplasia ossificans progressiva. N Engl J Med. 1996;335(8):555–61. https://doi.org/10.1056/NEJM199608223350804.CrossRefPubMed

28.

Kaplan FS, Glaser DL, Shore EM, Pignolo RJ, Xu M, Zhang Y, et al. Hematopoietic stem-cell contribution to ectopic skeletogenesis. J Bone Joint Surg Am. 2007;89(2):347–57. https://doi.org/10.2106/JBJS.F.00472.CrossRefPubMed

29.

Lounev VY, Ramachandran R, Wosczyna MN, Yamamoto M, Maidment AD, Shore EM, et al. Identification of progenitor cells that contribute to heterotopic skeletogenesis. J Bone Joint Surg Am. 2009;91(3):652–63. https://doi.org/10.2106/JBJS.H.01177.CrossRefPubMedPubMedCentral

30.

Chakkalakal SA, Zhang D, Culbert AL, Convente MR, Caron RJ, Wright AC, et al. An Acvr1 R206H knock-in mouse has fibrodysplasia ossificans progressiva. J Bone Miner Res. 2012;27(8):1746–56. https://doi.org/10.1002/jbmr.1637.CrossRefPubMed

31.

• Wang X, Li F, Xie L, Crane J, Zhen G, Mishina Y, et al. Inhibition of overactive TGF-beta attenuates progression of heterotopic ossification in mice. Nat Commun. 2018;9(1):551. https://doi.org/10.1038/s41467-018-02988-5This paper suggests the importance of TGF-beta signaling in FOP, indicating TGF-beta is a potential therapeutic target. CrossRefPubMedPubMedCentral

32.

Champagne CM, Takebe J, Offenbacher S, Cooper LF. Macrophage cell lines produce osteoinductive signals that include bone morphogenetic protein-2. Bone. 2002;30(1):26–31.CrossRefPubMed

33.

Del Zotto G, Antonini F, Azzari I, Ortolani C, Tripodi G, Giacopelli F, et al. Peripheral blood mononuclear cell immunophenotyping in fibrodysplasia ossificans progressiva patients: evidence for monocyte DNAM1 up-regulation. Cytometry B Clin Cytom. 2018;94(4):613–22. https://doi.org/10.1002/cyto.b.21594.CrossRefPubMed

34.

Gannon FH, Valentine BA, Shore EM, Zasloff MA, Kaplan FS. Acute lymphocytic infiltration in an extremely early lesion of fibrodysplasia ossificans progressiva. Clin Orthop Relat Res. 1998;346:19–25.CrossRef

35.

Kan L, Hu M, Gomes WA, Kessler JA. Transgenic mice overexpressing BMP4 develop a fibrodysplasia ossificans progressiva (FOP)-like phenotype. Am J Pathol. 2004;165(4):1107–15. https://doi.org/10.1016/S0002-9440(10)63372-X.CrossRefPubMedPubMedCentral

36.

Kan L, Liu Y, McGuire TL, Berger DM, Awatramani RB, Dymecki SM, et al. Dysregulation of local stem/progenitor cells as a common cellular mechanism for heterotopic ossification. Stem Cells. 2009;27(1):150–6. https://doi.org/10.1634/stemcells.2008-0576.CrossRefPubMedPubMedCentral

37.

Ranganathan K, Agarwal S, Cholok D, Loder S, Li J, Sung Hsieh HH, et al. The role of the adaptive immune system in burn-induced heterotopic ossification and mesenchymal cell osteogenic differentiation. J Surg Res. 2016;206(1):53–61. https://doi.org/10.1016/j.jss.2016.04.040.CrossRefPubMedPubMedCentral

38.

Wang H, Lindborg C, Lounev V, Kim JH, McCarrick-Walmsley R, Xu M, et al. Cellular hypoxia promotes heterotopic ossification by amplifying BMP signaling. J Bone Miner Res. 2016;31(9):1652–65. https://doi.org/10.1002/jbmr.2848.CrossRefPubMed

39.

Gannon FH, Glaser D, Caron R, Thompson LD, Shore EM, Kaplan FS. Mast cell involvement in fibrodysplasia ossificans progressiva. Hum Pathol. 2001;32(8):842–8. https://doi.org/10.1053/hupa.2001.26464.CrossRefPubMed

40.

Convente MR, Chakkalakal SA, Yang E, Caron RJ, Zhang D, Kambayashi T, et al. Depletion of mast cells and macrophages impairs heterotopic ossification in an Acvr1(R206H) mouse model of fibrodysplasia ossificans progressiva. J Bone Miner Res. 2018;33(2):269–82. https://doi.org/10.1002/jbmr.3304.CrossRefPubMed

41.

Agarwal S, Loder S, Brownley C, Cholok D, Mangiavini L, Li J, et al. Inhibition of Hif1alpha prevents both trauma-induced and genetic heterotopic ossification. Proc Natl Acad Sci U S A. 2016;113(3):E338–47. https://doi.org/10.1073/pnas.1515397113.CrossRefPubMed

42.

Meyers C, Lisiecki J, Miller S, Levin A, Fayad L, Ding C, et al. Heterotopic ossification: a comprehensive review. JBMR Plus. 2019;3(4):e10172. https://doi.org/10.1002/jbm4.10172.CrossRefPubMedPubMedCentral

43.

Sullivan MP, Torres SJ, Mehta S, Ahn J. Heterotopic ossification after central nervous system trauma: a current review. Bone Joint Res. 2013;2(3):51–7. https://doi.org/10.1302/2046-3758.23.2000152.CrossRefPubMedPubMedCentral

44.

Qureshi AT, Crump EK, Pavey GJ, Hope DN, Forsberg JA, Davis TA. Early Characterization of blast-related heterotopic ossification in a rat model. Clin Orthop Relat Res. 2015;473(9):2831–9. https://doi.org/10.1007/s11999-015-4240-y.CrossRefPubMedPubMedCentral

45.

Sung Hsieh HH, Chung MT, Allen RM, Ranganathan K, Habbouche J, Cholok D, et al. Evaluation of salivary cytokines for diagnosis of both trauma-induced and genetic heterotopic ossification. Front Endocrinol. 2017;8:74. https://doi.org/10.3389/fendo.2017.00074.CrossRef

46.

Alexander KA, Tseng HW, Fleming W, Jose B, Salga M, Kulina I, et al. Inhibition of JAK1/2 tyrosine kinases reduces neurogenic heterotopic ossification after spinal cord injury. Front Immunol. 2019;10:377. https://doi.org/10.3389/fimmu.2019.00377.CrossRefPubMedPubMedCentral

47.

Genet F, Kulina I, Vaquette C, Torossian F, Millard S, Pettit AR, et al. Neurological heterotopic ossification following spinal cord injury is triggered by macrophage-mediated inflammation in muscle. J Pathol. 2015;236(2):229–40. https://doi.org/10.1002/path.4519.CrossRefPubMed

48.

Torossian F, Guerton B, Anginot A, Alexander KA, Desterke C, Soave S, et al. Macrophage-derived oncostatin M contributes to human and mouse neurogenic heterotopic ossifications. JCI insight. 2017;2(21). https://doi.org/10.1172/jci.insight.96034.

49.

Louie CE, Hong J, Bauer DF. Heterotopic ossification following suboccipital craniectomy decompression surgery for Chiari malformation type I: case report. J Neurosurg Pediatr. 2019:1–4. https://doi.org/10.3171/2019.1.PEDS18680.PubMed

50.

Newman EA, Holst DC, Bracey DN, Russell GB, Lang JE. Incidence of heterotopic ossification in direct anterior vs posterior approach to total hip arthroplasty: a retrospective radiographic review. Int Orthop. 2016;40(9):1967–73. https://doi.org/10.1007/s00264-015-3048-4.CrossRefPubMed

51.

Egan KP, Duque G, Keenan MA, Pignolo RJ. Circulating osteogentic precursor cells in non-hereditary heterotopic ossification. Bone. 2018;109:61–4. https://doi.org/10.1016/j.bone.2017.12.028.CrossRefPubMed

52.

Hoff P, Rakow A, Gaber T, Hahne M, Senturk U, Strehl C, et al. Preoperative irradiation for the prevention of heterotopic ossification induces local inflammation in humans. Bone. 2013;55(1):93–101. https://doi.org/10.1016/j.bone.2013.03.020.CrossRefPubMed

53.

Dighe AS, Yang S, Madhu V, Balian G, Cui Q. Interferon gamma and T cells inhibit osteogenesis induced by allogeneic mesenchymal stromal cells. J Orthop Res. 2013;31(2):227–34. https://doi.org/10.1002/jor.22212.CrossRefPubMed

54.

Botzoris VG, Argyropoulou MI, Voulgari PV, Zikou AK, Drosos AA. Heterotopic ossification in systemic sclerosis. Scand J Rheumatol. 2009;38(4):317–9. https://doi.org/10.1080/03009740902776919.CrossRefPubMed

55.

Eckardt JJ, Ivins JC, Perry HO, Unni KK. Osteosarcoma arising in heterotopic ossification of dermatomyositis: case report and review of the literature. Cancer. 1981;48(5):1256–61. https://doi.org/10.1002/1097-0142(19810901)48:5<1256::aid-cncr2820480534>3.0.co;2-4.CrossRefPubMed

56.

Preusse C, Allenbach Y, Hoffmann O, Goebel HH, Pehl D, Radke J, et al. Differential roles of hypoxia and innate immunity in juvenile and adult dermatomyositis. Acta Neuropathol Commun. 2016;4(1):45. https://doi.org/10.1186/s40478-016-0308-5.CrossRefPubMedPubMedCentral

57.

Jeziorska M, McCollum C, Wooley DE. Observations on bone formation and remodelling in advanced atherosclerotic lesions of human carotid arteries. Virchows Arch. 1998;433(6):559–65.CrossRefPubMed

58.

Steiner I, Kasparova P, Kohout A, Dominik J. Bone formation in cardiac valves: a histopathological study of 128 cases. Virchows Arch. 2007;450(6):653–7. https://doi.org/10.1007/s00428-007-0430-7.CrossRefPubMed

59.

Masi AT, Rodnan GP, Medsger TA, Altman RD, D'Angelo WA, Fries JF, et al. Preliminary criteria for the classification of systemic sclerosis (scleroderma). Subcommittee for scleroderma criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee. Arthritis Rheum. 1980;23(5):581–90.CrossRef

60.

Dalakas MC, Hohlfeld R. Polymyositis and dermatomyositis. Lancet. 2003;362(9388):971–82. https://doi.org/10.1016/S0140-6736(03)14368-1.CrossRefPubMed

61.

Hunt JL, Fairman R, Mitchell ME, Carpenter JP, Golden M, Khalapyan T, et al. Bone formation in carotid plaques: a clinicopathological study. Stroke. 2002;33(5):1214–9.CrossRefPubMed

62.

Mohler ER 3rd, Gannon F, Reynolds C, Zimmerman R, Keane MG, Kaplan FS. Bone formation and inflammation in cardiac valves. Circulation. 2001;103(11):1522–8. https://doi.org/10.1161/01.cir.103.11.1522.CrossRefPubMed

63.

Soor GS, Vukin I, Leong SW, Oreopoulos G, Butany J. Peripheral vascular disease: who gets it and why? A histomorphological analysis of 261 arterial segments from 58 cases. Pathology. 2008;40(4):385–91. https://doi.org/10.1080/00313020802036764.CrossRefPubMed

64.

Campbell GR, Campbell JH. Vascular smooth muscle and arterial calcification. Z Kardiol. 2000;89(Suppl 2):54–62.CrossRefPubMed

65.

Cheng SL, Shao JS, Charlton-Kachigian N, Loewy AP, Towler DA. MSX2 promotes osteogenesis and suppresses adipogenic differentiation of multipotent mesenchymal progenitors. J Biol Chem. 2003;278(46):45969–77. https://doi.org/10.1074/jbc.M306972200.CrossRefPubMed

66.

Liu T, Lin J, Ju T, Chu L, Zhang L. Vascular smooth muscle cell differentiation to an osteogenic phenotype involves matrix metalloproteinase-2 modulation by homocysteine. Mol Cell Biochem. 2015;406(1-2):139–49. https://doi.org/10.1007/s11010-015-2432-0.CrossRefPubMed

67.

Tintut Y, Alfonso Z, Saini T, Radcliff K, Watson K, Bostrom K, et al. Multilineage potential of cells from the artery wall. Circulation. 2003;108(20):2505–10. https://doi.org/10.1161/01.CIR.0000096485.64373.C5.CrossRefPubMed

68.

Medici D, Shore EM, Lounev VY, Kaplan FS, Kalluri R, Olsen BR. Conversion of vascular endothelial cells into multipotent stem-like cells. Nat Med. 2010;16(12):1400–6. https://doi.org/10.1038/nm.2252.CrossRefPubMedPubMedCentral

69.

Doherty MJ, Ashton BA, Walsh S, Beresford JN, Grant ME, Canfield AE. Vascular pericytes express osteogenic potential in vitro and in vivo. J Bone Miner Res. 1998;13(5):828–38. https://doi.org/10.1359/jbmr.1998.13.5.828.CrossRefPubMed

70.

Kuwana M, Okazaki Y, Kodama H, Izumi K, Yasuoka H, Ogawa Y, et al. Human circulating CD14+ monocytes as a source of progenitors that exhibit mesenchymal cell differentiation. J Leukoc Biol. 2003;74(5):833–45. https://doi.org/10.1189/jlb.0403170.CrossRefPubMed

71.

Weston AD, Rosen V, Chandraratna RA, Underhill TM. Regulation of skeletal progenitor differentiation by the BMP and retinoid signaling pathways. J Cell Biol. 2000;148(4):679–90. https://doi.org/10.1083/jcb.148.4.679.CrossRefPubMedPubMedCentral

72.

Pacifici M, Cossu G, Molinaro M, Tato F. Vitamin A inhibits chondrogenesis but not myogenesis. Exp Cell Res. 1980;129(2):469–74. https://doi.org/10.1016/0014-4827(80)90517-0.CrossRefPubMed

73.

• Chakkalakal SA, Uchibe K, Convente MR, Zhang D, Economides AN, Kaplan FS, et al. Palovarotene inhibits heterotopic ossification and maintains limb mobility and growth in mice with the human ACVR1(R206H) fibrodysplasia ossificans progressiva (FOP) mutation. J Bone Miner Res. 2016;31(9):1666–75. https://doi.org/10.1002/jbmr.2820Palovalone is a potential therapeutic agent which is currently being tested in clinical trials in FOP patients. It may function by both blocking chondrocyte mineralization as well as immune cell function. CrossRefPubMed

74.

Lees-Shepard JB, Nicholas SE, Stoessel SJ, Devarakonda PM, Schneider MJ, Yamamoto M, et al. Palovarotene reduces heterotopic ossification in juvenile FOP mice but exhibits pronounced skeletal toxicity. eLife. 2018;7. https://doi.org/10.7554/eLife.40814.

75.

Wheatley BM, Cilwa KE, Dey D, Qureshi AT, Seavey JG, Tomasino AM, et al. Palovarotene inhibits connective tissue progenitor cell proliferation in a rat model of combat-related heterotopic ossification. J Orthop Res. 2018;36(4):1135–44. https://doi.org/10.1002/jor.23747.CrossRefPubMed

76.

Laplante M, Sabatini DM. mTOR signaling in growth control and disease. Cell. 2012;149(2):274–93. https://doi.org/10.1016/j.cell.2012.03.017.CrossRefPubMedPubMedCentral

77.

Qureshi AT, Dey D, Sanders EM, Seavey JG, Tomasino AM, Moss K, et al. Inhibition of mammalian target of rapamycin signaling with rapamycin prevents trauma-induced heterotopic ossification. Am J Pathol. 2017;187(11):2536–45. https://doi.org/10.1016/j.ajpath.2017.07.010.CrossRefPubMedPubMedCentral

78.

Hino K, Zhao C, Horigome K, Nishio M, Okanishi Y, Nagata S, et al. An mTOR signaling modulator suppressed heterotopic ossification of fibrodysplasia ossificans progressiva. Stem Cell Reports. 2018;11(5):1106–19. https://doi.org/10.1016/j.stemcr.2018.10.007.CrossRefPubMedPubMedCentral

79.

IFOPA. Rapamycin Clinical Trial for FOP 2019. Available from: https://www.ifopa.org/rapamycin. Accessed 1 July 2019

80.

Kaplan FS, Zeitlin L, Dunn SP, Benor S, Hagin D, Al Mukaddam M, et al. Acute and chronic rapamycin use in patients with fibrodysplasia ossificans progressiva: a report of two cases. Bone. 2018;109:281–4. https://doi.org/10.1016/j.bone.2017.12.011.CrossRefPubMed

81.

Peterson JR, De La Rosa S, Eboda O, Cilwa KE, Agarwal S, Buchman SR, et al. Treatment of heterotopic ossification through remote ATP hydrolysis. Sci Transl Med. 2014;6(255):255ra132. https://doi.org/10.1126/scitranslmed.3008810.CrossRefPubMedPubMedCentral

82.

Zhang K, Wang L, Zhang S, Yu B, Liu F, Cui Z, et al. Celecoxib inhibits the heterotopic ossification in the rat model with Achilles tenotomy. Eur J Orthop Surg Traumatol 2013;23(2):145–148. https://doi.org/10.1007/s00590-012-0944-9.CrossRef

83.

Lavernia CJ, Contreras JS, Villa JM, Rossi MD. Celecoxib and heterotopic bone formation after total hip arthroplasty. J Arthroplast. 2014;29(2):390–2. https://doi.org/10.1016/j.arth.2013.06.039.CrossRef

84.

Robertson AD, Chiaramonti AM, Nguyen TP, Jaffe DE, Holmes RE, Hanna EL, et al. Failure of indomethacin and radiation to prevent blast-induced heterotopic ossification in a Sprague-Dawley rat model. Clin Orthop Relat Res. 2019;477(3):644–54. https://doi.org/10.1097/CORR.0000000000000594.CrossRefPubMed

Title: Inflammation in Fibrodysplasia Ossificans Progressiva and Other Forms of Heterotopic Ossification
Authors: Koji Matsuo
Robert Dalton Chavez
Emilie Barruet
Edward C. Hsiao
Publication date: 01-12-2019
Publisher: Springer US
Keywords: Cytokines
Fibrodysplasia Ossificans Progressiva
Published in: Current Osteoporosis Reports / Issue 6/2019
Print ISSN: 1544-1873
Electronic ISSN: 1544-2241
DOI: https://doi.org/10.1007/s11914-019-00541-x

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Inflammation in Fibrodysplasia Ossificans Progressiva and Other Forms of Heterotopic Ossification

Abstract

Purpose of review

Recent findings

Summary

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Purpose of review

Recent findings

Summary

Please log in to get access to this content

Other articles of this Issue 6/2019

Bone Marrow Adipose Tissue Quantification by Imaging

Aging and Mechanoadaptive Responsiveness of Bone

The Regulation of Marrow Fat by Vitamin D: Molecular Mechanisms and Clinical Implications

Monocyte Chemoattractant Protein-1 (MCP-1/CCL2) Drives Activation of Bone Remodelling and Skeletal Metastasis

Mechanical Regulation of the Maternal Skeleton during Reproduction and Lactation

Marrow Fat-Secreted Factors as Biomarkers for Osteoporosis